SAB Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary

SAB Biotherapeutics

16/05/2023 15:19

* SAB Biotherapeutics Inc  SABS.OQ  reported a quarterly
adjusted
loss of 15 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 8 cents per share.
    * Revenue fell 95.1% to $581.10 thousand from a year ago;
analysts
expected $2.36 million. 
    * SAB Biotherapeutics Inc's reported EPS for the quarter was
a
loss of 15 cents​.
    * The mean earnings estimate of analysts had risen by
about 20% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * SAB Biotherapeutics Inc shares had risen by 100.0% this
quarter and gained 49.2% so far this year.
    * The company reported a quarterly loss of $7.35 million.
    * Wall Street's median 12-month price target for SAB
Biotherapeutics Inc is $3.40 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
16 at 02:19 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.08          -0.15          Missed
 Dec. 31 2022      -0.03                         
 Sep. 30 2022      -0.16          -0.16          Met
 Jun. 30 2022      -0.17          -0.11          Beat